Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02849171 : Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Age ? 18 years

- Patient is able to provide written informed consent prior to study registration

- Histologically-confirmed high-grade glioma

- Completion of treatment with standard radiation (with or without concurrent therapy).

- Standard gadolinium-enhanced MRI changes that are considered indeterminate for tumor
progression vs. treatment-related changes by the neuroradiologist or clinician within
24 weeks of completion of radiation.

- Patients who require and agree to surgical resection of their evolving post-treatment
brain lesion (a clinical decision made prior to and independent of enrollment in this

Exclusion Criteria:

- Inability to undergo or cooperate with an MRI or PET scan (e.g., claustrophobia, metal

- Renal insufficiency with recent (<3 month old) creatinine > 2.0 mg/dL

- Pregnant or nursing female
LinksPermanent Link to THIS page:      |      Link to official listing
New York, New York
Facility: Memorial Sloan Kettering Cancer Center
Contact: Mariza Daras, MD Phone: 212-610-0239
Email not avaialable

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites